Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP:BAYRY)

11.09 +0.27 (+2.50%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Aktienges ADR

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug ↗
 
Via Benzinga
News headline image
7 Stocks Under $15 to Buy and Hold Forever ↗
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul. 
Via InvestorPlace
News headline image
Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops ↗
The companies hoped to reduce the risk of myriad complications for at-risk patients. 
Via Investor's Business Daily
News headline image
Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration ↗
 
Via Benzinga
News headline image
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug ↗
 
Via Benzinga
News headline image
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics ↗
 
Via Benzinga
News headline image
Recap: Bayer Q4 Earnings ↗
Bayer (OTC:BAYRY) reported its Q4 earnings results on Tuesday, March 1, 2022 at 01:30 AM. Here's what investors need to know about the announcement. Earnings Bayer beat... 
Via Benzinga
News headline image
This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence ↗
BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective,... 
Via Benzinga
News headline image
Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today? ↗
DNA stock is down even while Ginkgo Bioworks prepares to purchase a biotech business and a large research and development site. 
Via InvestorPlace
News headline image
Science Wednesday: 'Silent Spring' At 60; Preserved Baby Mammoth Found In Yukon; Filling Medical Imaging, Nursing Shortages ↗
(This marks the first installment of Benzinga’s new weekly series Science Wednesday, which provides an overview of news and milestones within the sciences.) 
Via Benzinga
News headline image
BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products ↗
 
Via Benzinga
News headline image
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch ↗
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. 
Via Benzinga
News headline image
7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend ↗
These seven blue-chip stocks are trading at relative bargains and they can all be added to your portfolio for less than $250. 
Via InvestorPlace
News headline image
Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off ↗
 
Via Benzinga
News headline image
Three Stocks To Buy In This Bear Market ↗
There’s a silver lining to the current bear market. It’s created great buying opportunities. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗
 
Via Benzinga
News headline image
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers ↗
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses? 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows ↗
22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET. 
Via Benzinga
News headline image
Investment Strategy Monthly Insights, April 2022 ↗
After four decades of low inflation, developed economies are grappling with an inflation spike. 
Via Talk Markets
News headline image
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs ↗
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
News headline image
Merck Projects $10 Billion From Its Next Blockbuster Segment; Will It Measure Up? ↗
Merck shares hit a six-month high Tuesday on the bullish projection. 
Via Investor's Business Daily
News headline image
What Stocks Do Well During a Bear Market? 7 Picks for a Downturn ↗
These are the best bear market stocks to invest in now. T, BG and CL are some great picks for investors looking to weather the storm. 
Via InvestorPlace
News headline image
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia ↗
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines." 
Via Benzinga
News headline image
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
News headline image
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them? ↗
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
News headline image
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer ↗
Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.